Follistatin 344 vs PNC-27
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 344Immune Support
PNC-27- Summary
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- Half-Life
- ~24–36 hours
- Not well established; estimated minutes to hours
- Admin Route
- SubQ, IM
- Intravenous (research), Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 100 mcg
- Not established for humans; research doses vary by cell line and model
- Frequency
- Once daily
- Not established for human use
- Key Benefits
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Side Effects
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Stacks With
- —
- —